Advertisement
New Zealand markets closed
  • NZX 50

    11,946.43
    +143.15 (+1.21%)
     
  • NZD/USD

    0.5945
    +0.0008 (+0.14%)
     
  • NZD/EUR

    0.5548
    +0.0002 (+0.04%)
     
  • ALL ORDS

    7,937.50
    -0.40 (-0.01%)
     
  • ASX 200

    7,683.00
    -0.50 (-0.01%)
     
  • OIL

    82.94
    +0.13 (+0.16%)
     
  • GOLD

    2,328.50
    -9.90 (-0.42%)
     
  • NASDAQ

    17,526.80
    +55.33 (+0.32%)
     
  • FTSE

    8,040.38
    -4.43 (-0.06%)
     
  • Dow Jones

    38,460.92
    -42.77 (-0.11%)
     
  • DAX

    18,088.70
    -48.95 (-0.27%)
     
  • Hang Seng

    17,295.93
    +94.66 (+0.55%)
     
  • NIKKEI 225

    37,683.95
    -776.13 (-2.02%)
     
  • NZD/JPY

    92.4890
    +0.3740 (+0.41%)
     

Is It Time To Buy US Physical Therapy Inc (NYSE:USPH)?

US Physical Therapy Inc (NYSE:USPH), a healthcare company based in United States, saw a significant share price rise of over 20% in the past couple of months on the NYSE. As a stock with high coverage by analysts, you could assume any recent changes in the company’s outlook is already priced into the stock. But what if there is still an opportunity to buy? Let’s examine U.S. Physical Therapy’s valuation and outlook in more detail to determine if there’s still a bargain opportunity. Check out our latest analysis for U.S. Physical Therapy

What is U.S. Physical Therapy worth?

According to my valuation model, the stock is currently overvalued by about 37.41%, trading at US$97.90 compared to my intrinsic value of $71.25. Not the best news for investors looking to buy! But, is there another opportunity to buy low in the future? Given that U.S. Physical Therapy’s share is fairly volatile (i.e. its price movements are magnified relative to the rest of the market) this could mean the price can sink lower, giving us another chance to buy in the future. This is based on its high beta, which is a good indicator for share price volatility.

What kind of growth will U.S. Physical Therapy generate?

NYSE:USPH Future Profit June 21st 18
NYSE:USPH Future Profit June 21st 18

Future outlook is an important aspect when you’re looking at buying a stock, especially if you are an investor looking for growth in your portfolio. Although value investors would argue that it’s the intrinsic value relative to the price that matter the most, a more compelling investment thesis would be high growth potential at a cheap price. With profit expected to grow by 52.69% over the next year, the near-term future seems bright for U.S. Physical Therapy. It looks like higher cash flows is on the cards for the stock, which should feed into a higher share valuation.

What this means for you:

Are you a shareholder? USPH’s optimistic future growth appears to have been factored into the current share price, with shares trading above its fair value. At this current price, shareholders may be asking a different question – should I sell? If you believe USPH should trade below its current price, selling high and buying it back up again when its price falls towards its real value can be profitable. But before you make this decision, take a look at whether its fundamentals have changed.

ADVERTISEMENT

Are you a potential investor? If you’ve been keeping tabs on USPH for some time, now may not be the best time to enter into the stock. The price has surpassed its true value, which means there’s no upside from mispricing. However, the positive outlook is encouraging for USPH, which means it’s worth diving deeper into other factors in order to take advantage of the next price drop.

Price is just the tip of the iceberg. Dig deeper into what truly matters – the fundamentals – before you make a decision on U.S. Physical Therapy. You can find everything you need to know about U.S. Physical Therapy in the latest infographic research report. If you are no longer interested in U.S. Physical Therapy, you can use our free platform to see my list of over 50 other stocks with a high growth potential.


To help readers see pass the short term volatility of the financial market, we aim to bring you a long-term focused research analysis purely driven by fundamental data. Note that our analysis does not factor in the latest price sensitive company announcements.

The author is an independent contributor and at the time of publication had no position in the stocks mentioned.